drug protocol number

RJ19/119/J

drug sponsor

King Abdullah International Medical Research Center (KAIMRC)

drug study

BRENTUXIMAB VEDOTIN , DOXORUBICIN HYDROCHLORIDE , VINBLASTINE SULPHATE , Dacarbazine

drug trial site

King Abdulaziz Medical City NG (Jeddah)

drug status

Rejected

drug phase